Drugs / Remternetug
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07346495 | Jan → Aug 2026 overdue | — | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07056309 | Jun → Dec 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04451408 | Jul 2020 → Nov 2024 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03720548 | Nov 2018 → May 2019 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06647498 | Nov 2024 → Mar 2034 expected | early-onset autosomal dominant Alzheimer disease | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05552157 | Nov 2024 → Mar 2034 expected | familial Alzheimer disease | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06653153 | Oct 2024 → Apr 2029 expected | Alzheimer disease | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05463731 | Aug 2022 → Apr 2024 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Remternetug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07056309 ↗ |
| Known as | LY3372993 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04451408 ↗ |
| Modality | Monoclonal antibody | “Remternetug is a monoclonal antibody.” NCT06647498 ↗ |
| Route | Intravenous | “Administered IV.” NCT03720548 ↗ |